Objective:

To discuss the regulatory pathway for new therapies and the design of clinical trials in ophthalmology.

Approach:

Key Findings:

• One clinical trial is legally required for drug approval, but two are often necessary for confirmatory evidence.
• Safety and efficacy must be demonstrated, with a focus on visual function as a primary endpoint for AMD trials.

Interpretation:

The discussion emphasizes the importance of planning for two trials in ophthalmology to ensure adequate safety data.

Limitations:

• The conversation does not address specific statistical methods or detailed regulatory processes.
• No data on the success rates of trials or specific examples of therapies were provided.

Conclusion:

The insights provided highlight the regulatory expectations and considerations for clinical trials in ophthalmology, particularly for AMD.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.